HC Wainwright Reiterates “Buy” Rating for BioLineRx (NASDAQ:BLRX)

BioLineRx (NASDAQ:BLRX)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports.

Several other brokerages have also issued reports on BLRX. Wall Street Zen began coverage on shares of BioLineRx in a research report on Sunday, May 18th. They issued a “sell” rating on the stock. Jones Trading raised shares of BioLineRx from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 30th.

BioLineRx Price Performance

Shares of NASDAQ:BLRX traded up $0.15 during trading on Tuesday, reaching $4.57. 56,733 shares of the company’s stock traded hands, compared to its average volume of 231,802. The firm has a market cap of $19.47 million, a PE ratio of -0.52 and a beta of 1.29. BioLineRx has a fifty-two week low of $2.30 and a fifty-two week high of $35.60. The company has a quick ratio of 2.04, a current ratio of 2.27 and a debt-to-equity ratio of 0.37. The company has a 50-day simple moving average of $3.72 and a 200-day simple moving average of $4.68.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Tuesday, May 27th. The biotechnology company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $2.23. BioLineRx had a negative return on equity of 23.93% and a negative net margin of 15.21%. The business had revenue of $11.75 million during the quarter, compared to analysts’ expectations of $7.72 million. As a group, analysts predict that BioLineRx will post -5.8 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BioLineRx stock. Highbridge Capital Management LLC bought a new stake in BioLineRx Ltd. (NASDAQ:BLRX) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned about 50.50% of BioLineRx as of its most recent SEC filing. Institutional investors own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.